Atherosclerosis Susceptibility (ATHS)

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Atherosclerosis Susceptibility

MalaCards integrated aliases for Atherosclerosis Susceptibility:

Name: Atherosclerosis Susceptibility 56
Atherosclerosis 56 12 74 29 54 42 43 15 62 17 71 32
Atherosclerosis, Susceptibility to 56 13 6
Atherogenic Lipoprotein Phenotype; Alp 56
Atherogenic Lipoprotein Phenotype 56
Arteriosclerosis 71
Aths 56
Alp 56



autosomal dominant
? same as ldlr


atherosclerosis susceptibility:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:1936
OMIM 56 108725
ICD9CM 34 440
MeSH 43 D050197
NCIt 49 C35768
SNOMED-CT 67 38716007
ICD10 32 I70
MedGen 41 C1531719
SNOMED-CT via HPO 68 190785000 22298006 263681008
UMLS 71 C0003850 C0004153

Summaries for Atherosclerosis Susceptibility

MedlinePlus : 42 Atherosclerosis is a disease in which plaque builds up inside your arteries. Plaque is a sticky substance made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows your arteries. That limits the flow of oxygen-rich blood to your body. Atherosclerosis can lead to serious problems, including Coronary artery disease. These arteries supply blood to your heart. When they are blocked, you can suffer angina or a heart attack. Carotid artery disease. These arteries supply blood to your brain. When they are blocked you can suffer a stroke. Peripheral arterial disease. These arteries are in your arms, legs and pelvis. When they are blocked, you can suffer from numbness, pain and sometimes infections. Atherosclerosis usually doesn't cause symptoms until it severely narrows or totally blocks an artery. Many people don't know they have it until they have a medical emergency. A physical exam, imaging, and other diagnostic tests can tell if you have it. Medicines can slow the progress of plaque buildup. Your doctor may also recommend procedures such as angioplasty to open the arteries, or surgery on the coronary or carotid arteries. Lifestyle changes can also help. These include following a healthy diet, getting regular exercise, maintaining a healthy weight, quitting smoking, and managing stress. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Atherosclerosis Susceptibility, also known as atherosclerosis, is related to generalized atherosclerosis and hepatic lipase deficiency, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Atherosclerosis Susceptibility is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Binding and Uptake of Ligands by Scavenger Receptors and Folate Metabolism. The drugs Aspirin and Rimonabant have been mentioned in the context of this disorder. Affiliated tissues include Heart, and related phenotypes are hypertriglyceridemia and myocardial infarction

OMIM : 56 The atherogenic lipoprotein phenotype (ALP) is a common heritable trait characterized by a preponderance of small, dense low density lipoprotein (LDL) particles (subclass pattern B), increased levels of triglyceride-rich lipoproteins, reduction in high density lipoprotein, and a 3-fold increased risk of myocardial infarction (summary by Nishina et al., 1992). The so-called atherogenic lipoprotein phenotype was shown by Austin et al. (1988) to be independently associated with an increased risk for coronary artery disease. Allayee et al. (1998) concluded, furthermore, that there is a genetically based association between familial combined hyperlipidemia (FCHL; 144250) and small, dense LDL particles and that the genetic determinants for LDL particle size are shared, at least in part, among FCHL families and the more general population at risk for coronary artery disease. Juo et al. (1998) concluded from a bivariate segregation analysis of small, dense LDL particles and elevated apolipoprotein B levels (APOB; 107730), which are commonly found together in members of FCHL families, that the 2 traits share a common major gene plus individual polygenic components. The common major gene was estimated to explain 37% of the variance of adjusted LDL particle size and 23% of the variance of adjusted apoB levels. (108725)

PubMed Health : 62 About atherosclerosis: Atherosclerosis (ath-er-o-skler-O-sis) is a disease in which plaque (plak) builds up inside your arteries. Arteries are blood vessels that carry oxygen-rich blood to your heart and other parts of your body. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows your arteries. This limits the flow of oxygen-rich blood to your organs and other parts of your body. Atherosclerosis can lead to serious problems, including heart attack, stroke, or even death.

Wikipedia : 74 Atherosclerosis is a disease in which the inside of an artery narrows due to the buildup of plaque.... more...

Related Diseases for Atherosclerosis Susceptibility

Diseases related to Atherosclerosis Susceptibility via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1188)
# Related Disease Score Top Affiliating Genes
1 generalized atherosclerosis 35.0 INS CRP APOE APOB
2 hepatic lipase deficiency 33.6 APOE APOA1
3 carotid artery disease 33.4 CRP CCL2 APOE APOB APOA1
4 carotid stenosis 33.4 VCAM1 CRP CDKN2B-AS1 APOE
5 familial lcat deficiency 33.4 APOE APOA1
6 tangier disease 33.4 APOE APOB APOA1 ABCA1
7 cerebrovascular disease 33.4 VCAM1 TLR4 INS CRP APOE APOB
8 angina pectoris 33.3 INS CRP APOA1
9 sitosterolemia 33.3 APOB APOA1 ABCA1
10 homocysteinemia 33.3 VCAM1 H19 CRP CCL2 APOE
11 familial hypercholesterolemia 33.3 INS CRP APOE APOB APOA1 ABCA1
12 hypoalphalipoproteinemia, primary, 2 33.1 APOA1 ABCA1
13 peripheral vascular disease 32.9 VCAM1 INS CRP CCL2 APOB APOA1
14 coronary heart disease 1 32.8 VCAM1 INS H19 CRP CDKN2B-AS1 APOE
15 hyperlipoproteinemia, type iv 32.7 APOE APOB APOA1
16 non-alcoholic fatty liver disease 32.0 TLR4 INS HMOX1 CRP APOB APOA1
17 peripheral artery disease 32.0 VCAM1 HMOX1 CRP CDKN2B-AS1 CCL2 APOE
18 chronic kidney disease 32.0 VCAM1 TUG1 TLR4 INS HMOX1 CRP
19 diabetes mellitus 31.9 VCAM1 TUG1 TLR4 INS HMOX1 CRP
20 sleep apnea 31.9 VCAM1 INS CRP CCL2 APOE APOB
21 heart disease 31.9 VCAM1 TLR4 INS HMOX1 H19 CRP
22 aortic aneurysm, familial abdominal, 1 31.9 H19 CRP CDKN2B-AS1 CCL2 APOE
23 glucose intolerance 31.8 INS CRP CCL2 APOB APOA1
24 stroke, ischemic 31.8 TLR4 CRP CDKN2B-AS1 APOE APOB ALOX5
25 antiphospholipid syndrome 31.7 VCAM1 TLR4 CRP
26 cardiovascular system disease 31.7 VCAM1 TLR4 INS HMOX1 CRP CDKN2B-AS1
27 body mass index quantitative trait locus 11 31.7 VCAM1 TLR4 INS HMOX1 H19 CRP
28 lipid metabolism disorder 31.7 INS CRP CCL2 APOE APOB APOA1
29 hypertension, essential 31.6 VCAM1 TLR4 INS HMOX1 CRP CDKN2B-AS1
30 homozygous familial hypercholesterolemia 31.6 APOE APOB APOA1 ABCA1
31 uremia 31.6 INS CRP APOA1
32 non-alcoholic steatohepatitis 31.6 TLR4 INS CCL2 APOE
33 pulmonary disease, chronic obstructive 31.5 TUG1 TLR4 INS HMOX1 CRP CCL2
34 retinal vascular disease 31.5 VCAM1 INS CRP CCL2
35 hyperlipidemia, familial combined, 3 31.5 INS APOE APOB APOA1
36 lipid storage disease 31.5 TLR4 INS CRP CCL2 APOB
37 familial hyperlipidemia 31.5 INS CRP APOE APOB APOA1 ABCA1
38 hyperlipoproteinemia, type iii 31.5 APOE APOB APOA1
39 macular degeneration, age-related, 1 31.4 TLR4 INS HMOX1 CRP CCL2 APOE
40 acute insulin response 31.4 INS CRP
41 apnea, obstructive sleep 31.4 INS CRP APOE
42 pre-eclampsia 31.3 VCAM1 TUG1 TLR4 INS HMOX1 H19
43 aortic atherosclerosis 31.3 TLR4 APOE APOB APOA1 ABCA1
44 lipoprotein quantitative trait locus 31.3 VCAM1 CRP APOB APOA1
45 arteries, anomalies of 31.3 VCAM1 INS CRP CCL2 APOE APOB
46 pneumonia 31.3 TLR4 HMOX1 CRP CCL2
47 peritonitis 31.3 VCAM1 TLR4 CRP CCL2
48 vascular dementia 31.3 CRP APOE APOA1
49 dilated cardiomyopathy 31.2 VCAM1 TLR4 HMOX1 CRP CCL2 APOE
50 amyloidosis 31.2 INS CRP APOE APOA1

Graphical network of the top 20 diseases related to Atherosclerosis Susceptibility:

Diseases related to Atherosclerosis Susceptibility

Symptoms & Phenotypes for Atherosclerosis Susceptibility

Human phenotypes related to Atherosclerosis Susceptibility:

# Description HPO Frequency HPO Source Accession
1 hypertriglyceridemia 31 HP:0002155
2 myocardial infarction 31 HP:0001658
3 decreased hdl cholesterol concentration 31 HP:0003233

Symptoms via clinical synopsis from OMIM:

increased myocardial infarction risk

preponderance of small, dense low density lipoprotein (ldl) particles (subclass pattern b)
increased triglyceride-rich lipoproteins
reduced high density lipoprotein

Clinical features from OMIM:


UMLS symptoms related to Atherosclerosis Susceptibility:

edema, chest pain, angina pectoris

GenomeRNAi Phenotypes related to Atherosclerosis Susceptibility according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.32 ABCA1

MGI Mouse Phenotypes related to Atherosclerosis Susceptibility:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 ABCA1 ALOX5 APOA1 APOB APOE CRP
2 liver/biliary system MP:0005370 9.17 ABCA1 APOA1 APOB APOE HMOX1 INS

Drugs & Therapeutics for Atherosclerosis Susceptibility

PubMed Health treatment related to Atherosclerosis Susceptibility: 62

Treatments for atherosclerosis may include lifestyle changes, medicines, and medical procedures or surgery . The goals of treatment include: Relieving symptoms Reducing risk factors in an effort to slow or stop the buildup of plaque Lowering the risk of blood clots forming Widening or bypassing plaque -clogged arteries Preventing atherosclerosis -related diseases

Drugs for Atherosclerosis Susceptibility (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 746)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Rimonabant Approved, Investigational Phase 4 158681-13-1, 168273-06-1 104850
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
Mirabegron Approved Phase 4 223673-61-8 9865528
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Insulin detemir Approved Phase 4 169148-63-4 5311023
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Remifentanil Approved Phase 4 132875-61-7 60815
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Pravastatin Approved Phase 4 81093-37-0 54687
Chromium Approved Phase 4 7440-47-3 27668
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
Acetaminophen Approved Phase 4 103-90-2 1983
Saxagliptin Approved Phase 4 361442-04-8 11243969
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
Phylloquinone Approved, Investigational Phase 4 84-80-0
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Warfarin Approved Phase 4 81-81-2 6691 54678486
Ticlopidine Approved Phase 4 55142-85-3 5472
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
Caffeine Approved Phase 4 58-08-2 2519
Sevelamer Approved Phase 4 52757-95-6
35 Tomato Approved Phase 4
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
Calcium acetate Approved, Investigational Phase 4 62-54-4
Gliclazide Approved Phase 4 21187-98-4 3475
Glyburide Approved Phase 4 10238-21-8 3488
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
Adalimumab Approved Phase 4 331731-18-1 16219006
Anthralin Approved Phase 4 1143-38-0
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Racepinephrine Approved Phase 4 329-65-7 838
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
Insulin lispro Approved Phase 4 133107-64-9
Insulin glargine Approved Phase 4 160337-95-1

Interventional clinical trials:

(show top 50) (show all 3131)
# Name Status NCT ID Phase Drugs
1 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
2 Phase 3 Study of Atorvastatin Effects on Carotid Atherosclerosis Unknown status NCT00640744 Phase 4 Atorvastatin
3 Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women Unknown status NCT00154180 Phase 4 Conjugated equine estrogens 0.45 mg/day;Transdermal estradiol, 50 mcg/day;Micronized progesterone, 200 mg/day x 12 d/month;CEE , progesterone, estradiol patch or placebo for each;CEE, progesterone, transdermal patch or the placebo
4 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
5 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
6 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
7 Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial Unknown status NCT02796664 Phase 4
8 A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD) Unknown status NCT02502981 Phase 4 Spironolactone;Chlortalidone
9 Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) Unknown status NCT00217178 Phase 4 Vitamins: Folic acid, B6, B12
10 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
11 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques. Unknown status NCT01773512 Phase 4 Rosuvastatin
12 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
13 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
14 The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients Unknown status NCT00470808 Phase 4 POMx
15 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis Progression and Epicardial Adipose Tissue(EAT) Volume Reduction in Patients With Coronary Atherosclerosis Detected by Coronary CT Angiography(CCTA) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
16 Effect of Bydureon on Carotid Atherosclerosis Progression in T2DM Unknown status NCT02162550 Phase 4 Bydureon;placebo
17 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
18 A 2-year, Open-label, Randomized Study to Evaluate the Efficacy of Rosuvastatin Dosing Adjustment by LDL-C Level Compared to That of 5mg Maintenance Dose in Chinese Patients With Carotid Atherosclerotic Plaques Unknown status NCT02532309 Phase 4 Rosuvastatin (5mg,10mg,20mg);Rosuvastatin 5mg
19 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
20 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
21 A 104-week, Open-label, Single-group Study: Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH) Unknown status NCT00885872 Phase 4 Rosuvastatin (Crestor)
22 The Effect of Dates on Plasma Lipids, Oxidative Stress and the Atherogenicity of Serum in Healthy Adults Unknown status NCT00750789 Phase 4
23 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
24 The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Atherosclerosis Unknown status NCT00963222 Phase 4 vitamin A;placebo
25 Effect of Atorvastatin on Inflammatory Atherosclerotic Plaques Assessed by FDG-PET Imaging Unknown status NCT00920101 Phase 4 Atorvastatin
26 To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject Unknown status NCT02098460 Phase 4 Atorvastatin, Probucol, Cilostazol
27 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
28 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
29 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
30 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
31 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
32 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
33 The Effect of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by T CD4+ Lymphocyte in Atherosclerotic Patients Unknown status NCT01414972 Phase 4 Vitamin A;placebo
34 Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Randomized Controlled Trial in Patients With Advanced Atherosclerosis. Unknown status NCT00711984 Phase 4
35 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
36 Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study Unknown status NCT02299245 Phase 4 rosuvastatin
37 the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy Unknown status NCT03230851 Phase 4 aspirin 100mg/d therapy;aspirin 100mg/2d therapy;aspirin 100mg/3d therapy;aspirin 50mg bid therapy;aspirin 75mg/d therapy;aspirin 50mg/d therapy;indobufen 100mg bid therapy
38 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
39 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
40 Does Rosuvastatin Delay Progression of Atherosclerosis in People With HIV Infection at Moderate Cardiovascular Risk? A Multicentre Randomized, Double Blind Placebo-controlled Trial Unknown status NCT01813357 Phase 4 Rosuvastatin
41 Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
42 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
43 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
44 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome Unknown status NCT00988364 Phase 4 Simvastatin;Vytorin;Placebo;Ezetimibe
45 Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function Unknown status NCT02584075 Phase 4 Byetta (Exenatide);Glucophage ( Metformin Hydrochloride)
46 Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
47 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
48 Type 2 Diabetes Mellitus: Role of Inflammation and Innate Immunity in The Pathogenesis of Endothelial Dysfunction and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
49 Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke Unknown status NCT03252626 Phase 4 Alprostadil;Normal saline
50 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg

Search NIH Clinical Center for Atherosclerosis Susceptibility

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Epoprostenol Sodium
Isoxsuprine Hydrochloride

Cochrane evidence based reviews: atherosclerosis

Genetic Tests for Atherosclerosis Susceptibility

Genetic tests related to Atherosclerosis Susceptibility:

# Genetic test Affiliating Genes
1 Atherosclerosis 29

Anatomical Context for Atherosclerosis Susceptibility

MalaCards organs/tissues related to Atherosclerosis Susceptibility:

Endothelial, Heart, Kidney, Monocytes, Smooth Muscle, Liver, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Atherosclerosis Susceptibility:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Coronary Capillary Plexus Affected by disease
2 Heart Coronary Vessels Affected by disease
3 Endothelium Arteries Arterial Endothelial Cells Affected by disease

Publications for Atherosclerosis Susceptibility

Articles related to Atherosclerosis Susceptibility:

(show top 50) (show all 33589)
# Title Authors PMID Year
Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. 6 54 61
14702425 2004
Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19. 56 61 54
1731344 1992
VEGF polymorphisms and severity of atherosclerosis. 61 6
15937083 2005
Multilocus genetic determinants of LDL particle size in coronary artery disease families. 56 54
8644718 1996
Epigenetic control of atherosclerosis via DNA methylation: A new therapeutic target? 61 42
32387418 2020
Aging-related atherosclerosis is exacerbated by arterial expression of tumor necrosis factor receptor-1: evidence from mouse models and human association studies. 56
20421368 2010
Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. 6
18413368 2009
Vascular endothelial growth factor gene variability is associated with increased risk for AD. 6
15732116 2005
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. 6
10369259 1999
A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. 56
9683593 1998
Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype. 56
9683614 1998
The atherogenic lipoprotein phenotype is not caused by a mutation in the coding region of the low density lipoprotein receptor gene. 56
9184244 1997
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. 6
9062372 1997
Low-density lipoprotein subclass patterns and risk of myocardial infarction. 56
3418853 1988
In silico analysis of the molecular regulatory networks in peripheral arterial occlusive disease. 42
32481342 2020
Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. 42
32386592 2020
Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. 61 54
19687018 2010
Extracellular phospholipases in atherosclerosis. 54 61
20153800 2010
Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. 54 61
20154064 2010
Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. 61 54
20439543 2010
Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. 61 54
20395699 2010
Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. 61 54
20444418 2010
Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis. 61 54
20360257 2010
Associations between plasma C-reactive protein levels and the severities of coronary and aortic atherosclerosis. 61 54
20134100 2010
Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. 61 54
20167662 2010
Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein E knockout mice. 61 54
20182519 2010
MMP2 genetic variation is associated with measures of fibrous cap thickness: The Atherosclerosis Risk in Communities Carotid MRI Study. 61 54
20064641 2010
Soluble epoxide hydrolase in atherosclerosis. 54 61
20425256 2010
Toll like receptor 4 in atherosclerosis and plaque destabilization. 54 61
19900676 2010
[Association of the ALOX5AP gene SG13S114 A/T polymorphism with atherosclerosis]. 54 61
20376802 2010
Interleukin-18 gene polymorphism and markers of subclinical atherosclerosis. The Cardiovascular Risk in Young Finns Study. 54 61
20350254 2010
Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. 54 61
19931584 2010
Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. 54 61
19896127 2010
Association between platelet endothelial cellular adhesion molecule-1 polymorphisms and atherosclerosis: results of a study on patients from northern Italy. 54 61
20370486 2010
Proteomic profiling in apolipoprotein E-deficient mice during atherosclerosis progression. 61 54
19230958 2010
Accelerated atherosclerosis in rheumatoid arthritis: rationale for mannose-binding lectins? 61 54
20197564 2010
Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. 61 54
19766217 2010
Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. 54 61
20110287 2010
[Effects of PPARgamma agonist on dyslipidemia and atherosclerosis]. 61 54
20158099 2010
Regulations of the key mediators in inflammation and atherosclerosis by aspirin in human macrophages. 54 61
20137092 2010
Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. 61 54
19910639 2010
Characteristics of apolipoprotein M and its relation to atherosclerosis and diabetes. 61 54
19909825 2010
Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. 61 54
20145358 2010
[LOX-1 receptor as a novel target in endothelial dysfunction and atherosclerosis]. 54 61
20146162 2010
Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. 54 61
20142250 2010
Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. 61 54
20124121 2010
Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. 54 61
19834878 2010
[Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice]. 54 61
20158089 2010
Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. 54 61
20078196 2010
Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. 61 54
20221877 2010